Open AccessLAAE‐14, a new anti‐inflammatory drug, increases the survival of Candida albicans ‐inoculated mice
Author(s) -
Lucas Rut,
Villamón Eva,
Payá Miguel,
Alves Mario,
Olmo Esther,
Gozalbo Daniel,
Gil M.Luisa
Publication year - 2004
Publication title -
fems immunology & medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1574-695X
pISSN - 0928-8244
DOI - 10.1016/s0928-8244(03)00371-7
Subject(s) - candida albicans , biology , drug , inoculation , microbiology and biotechnology , immunology , pharmacology
LAAE‐14, a lipidic acid‐amido ether derivative, has been recently described as a new anti‐inflammatory drug. We have studied the effect of treatment with this compound on the susceptibility of mice to in vivo experimental Candida albicans infection. ICR mice orally treated with LAAE‐14 (25 mg kg −1 ) and experimentally intravenously infected showed a significantly increased survival as compared to control mice. In vitro, the compound did not inhibit the growth of C. albicans yeast cells or the yeast‐to‐hyphal transition. The in vitro production of prostaglandin E 2 by peritoneal macrophages in response to the yeasts and hyphae of C. albicans was significantly decreased upon treatment with LAAE‐14, in a dose‐dependent manner. Thus, reduced prostaglandin production during fungal infection could be an important factor in controlling fungal colonisation and infection.